Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510

RÉCEIVED SECRETARY OF THE SENA PUBLIC RECORDS

02 FEB -8 PM 12: 2

LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page

1. Registrant Name Novartis	
	Suite 725 DC 20004
Principal Place of Business (if different from line 2) City State/Zip (or Country)	·.
4. Contact Name E-ma Burt Rosen 202-638-7429	5. Senate ID # 9204-12
7. Client Name Self Novartis Corporation	6. House ID # 33589000
TYPE OF REPORT 8. Year 2001 Midyear 9. Check if this filing amends a previously filed version of the 10. Check if this is a Termination Report >> Termination INCOME OR EXPENSES - Complete Either	n Date 11. No Lobbyi
12. Lobbying Firms	13. Organizations
INCOME relating to lobbying activities for this reporting period was:	EXPENSES relating to lobbying activities for this report period were:
\$10,000 or more	Less than \$10,000 \$10,000 or more \$\simeq \simeq \simeq \simeq \simeq \\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$\\$
Signature Rurt Rosen - Senior Vice President Filing #e2656c93-8772-4a02-91cc-f040	Date 7/03

Printed Name	and Title	 Delliol Fice	i i voitaviit	 	 Pag
					ی
<u> </u>					

Reg	istrant Name:	Novartis	:
Clie	nt Name:	Novartis Corporation	
enga	aged in lobby	TIVITY. Select as many codes as necessaring on behalf of the client during the reportiquested. Attach additional page(s) as needed	y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provide .
15.	General issu	e area code BUD (one per page)	
16.	Specific Lot	bying issues	
	Appropriat		<u>.</u>
	Appropriat	ons: USDA	
	! !		
			ų.
	į		
			;
17	House(s) of	Congress and Federal agencies contacted	
17.		presentatives	☐ Check if None
	Senate	•	;
18.	Name of eac	h individual who acted as a lobbyist in this	
	Name		Covered Official Position (if applicable)
	Bumbaugh,	Deborah	
	Drake, Davi	d	
	Elkin, Jame	S	
	!		
	<u>'</u>		
	<u>-</u>		
	l		9u .
	:		
			·
19.	Novartis AG	ch foreign entity in the specific issues listed. To the degree that public policies, either AG, as its parent, will benefit.	on line 16 above
	11	2-1-1	$ \frac{1}{2}\sqrt{2}\sqrt{2}$
Sign	ature	DIM KDA	Date Of // ()

Rurt Docan - Saniar Vice President Filing #e2656c93-8772-4a02-91cc-f04062762ab0 - Page 3 of 22

Printed Name and Title	Durt Moseii - Bellioi Vice I fesidelit	 Pas
		* **

Registrant Name	e: Novartis	
Client Name:	Novartis Corporation	D.
LOBBYING A	CTIVITY. Select as many codes as necessar	y to reflect the general issue areas in which the registrant
engaged in lobb	ying on behalf of the client during the reporti	ing period. Using a separate page for each code, provid
	eğuested. Attach additional page(s) as needec	
15. General iss		
16. Specific Lo S.754/H.R	obbying issues .1,063, Increasing Ability to Enforce Antitr	rust Laws.
S.812/H.R	.1862, Greater Access to Affordable Pharm	naceuticals Act,
	in the second se	
	f Congress and Federal agencies contacted	☐ Check if None
House of F Senate	Representatives	
Senate		
		, .
		•
18. Name of ea	individual who acted as a lobbyist in this	issue area
2.7		
Name	4	Covered Official Position (if applicable)
Casserly, I	Dận	
Drake, Da	vid	
Elkin, Jam	A A	
Eikili, vali		
	# 	
	6 4 3	a sulfa
	:: 1 1	
19. Interest of a	each foreign entity in the specific issues listed	d on line 16 above Check if None
Novartis A	To the degree that public policies, either	r laws or regulations, commercially benefit Novartis (
too Novart	tis AG, as its parent, will benefit	
•	* KAD	_ / /
Signature	i DM Kese-	

Rurt Rosen - Senior Vice President Filing #e2656c93-8772-4a02-91cc-f04062762ab0 - Page 5 of 22

rinted Name and Tit	 		
JJ			
1			
<u> </u>		•	

Reg	istrant Name: Novartis	
Clie	nt Name: Novartis Corporation	
enga	aged in lobbying on behalf of the client during the report rmation as requested. Attach additional page(s) as neede	
16.	National Uniformity for Food Genetically Engineered Food Right to Know Act Country of Origin Labeling GMO Labeling	
17.	House(s) of Congress and Federal agencies contacted Department of Agriculture Environmental Protection Agency Food & Drug Administration House of Representatives Senate	☐ Check if None
18.	Name of each individual who acted as a lobbyist in this	I
	Name	Covered Official Position (if applicable)
	Drake, David	
	Elkin, James	
	Haller, Sarah	
	Rosen, Burt	
		V 19
	Interest of each foreign entity in the specific issues liste Novartis AG To the degree that public policies, eithe too Novartis AG, as its parent, will benefit.	d on line 16 above

Rurt Rosen - Senior Vice President Filing #e2656c93-8772-4a02-91cc-f04062762ab0 - Page 7 of 22

Reg	istrant Name: Novartis	
Clie	ent Name: Novartis Corporation	
enga info	BBYING ACTIVITY. Select as many codes as necessary aged in lobbying on behalf of the client during the reportion as requested. Attach additional page(s) as needed General issue area code HCR (one per page) Specific Lobbying issues H.R. 1387, Drug Availablity and Health Care Access H.R.1530, Prescription Drug Competition Act of 200 H.R.1624/S 913, Access to Cancer Therapies Act of 2 S. 1239, Medicare Rx Drug Discount and Security Act S.10, Medicare Prescription Drug Coverage Act of 2 S.1135, Medicare Reform Act of 2001, S.1185, Seniors Prescription Insurance Coverage Eq S.838 IS, Better Pharmaceuticals for Children Act, S.880/H.R.1839, Immunosuppressive Drug Coverage S.982 IS /H.R.2058 IH, Medicare Wellness Act of 200	Improvement Act of 2001, 1, 001, ct of 2001, uity Act of 2001, Act of 2001,
17.	House(s) of Congress and Federal agencies contacted Drug Enforcement Administration Food & Drug Administration House of Representatives Senate	☐ Check if None
18.	Name of each individual who acted as a lobbyist in this i	ssue area Covered Official Position (if applicable)
	Bumbaugh, Deborah	
	Casserly, Dan	
	Drake, David	i
	Elkin, James	
	Haller, Sarah	, <u> </u>
· 4	Rosen, Burt	· - 4 ·
	Interest of each foreign entity in the specific issues listed Novartis AG To the degree that public policies, either too Novartis AG, as its parent, will benefit. Additional acture Additional Additionaly Additional Additional Additional Additional Additional Addition	on line 16 above

Rurt Rosan - Saniar Vice President Filing #e2656c93-8772-4a02-91cc-f04062762ab0 - Page 9 of 22 Registrant Name:

Novartis

Client Name:

Novartis Corporation

Item	Description	Data
16	Lobbying Issues	Medicare Prescription Drugs
		Snowe/Wyden The Senior Prescription Insurance Coverage Equity Act (S.11
		Breaux/Thomas Medicare Reform Plan
		Health Insurance Portability and Accessibility Act
		FDA Modernization Act
	;	Medical Records Privacy - Senators Jeffords, Bennett, Leahy, Kennedy Bills
	- I	Prospective Payment System
	r H	Gene Therapy
		Drug Reimportation
		Medicare Reform
	· ·	Agriculture Appropriations 2001 - Drug Reimportation
		Agriculture Appropriation 2001 (FDA funding)
	9	Stem Cell Research
		Pediatric Exclusivity
		Direct-to-Consumer Advertising
	; 1	PDUFA
	1	The Bipartisan Medicare Prescription Drug Act of 2001 (Sen. Kennedy-Draf
		President Bush's "Helping Hand" proposal
	e e	
	i,	

Reg	istrant Name: Novartis	·-	
Clie	nt Name: Novartis Corporation	- -	
enga info	BBYING ACTIVITY. Select as many codes as maged in lobbying on behalf of the client during the rmation as requested. Attach additional page(s) as General issue area code MMM (one per Specific Lobbying issues H.R. 1530, Prescription Drug Competition Act H.R.1387, Drug Availability and Health Care HR1624/S913, Access to Cancer Therapies Act S. 10, Medicare Prescription Drug Coverage Act S.1135, Medicare Reform Act of 2001, S.1185, Seniors Prescription Insurance Coverage S.1239, Medicare Rx Drug Discount & Securit S.880/H.R.1839, Immunosuppressive Drug Co S.982 IS/H.R. 2058 IH, Medicare Wellness Act	e reporting periods aneeded. or page) et of 2001, Access Improve et, Act of 2001, age Equity Act of y Act of 2001, overage Act of 2	d. Using a separate page for each code, provide ement Act of 2001,
17.	House(s) of Congress and Federal agencies contained to the Human Services Food & Drug Administration House of Representatives Senate	acted	☐ Check if None
18.	Name of each individual who acted as a lobbyist	in this issue area	a
	Name	Cove	red Official Position (if applicable)
	Bumbaugh, Deborah		
	Casserly, Dan		
•	Drake, David		
	Elkin, James		
	Haller, Sarah		
	Rosen, Burt		N.
19.	Interest of each foreign entity in the specific issue Novartis AG To the degree that public policies too Novartis AG, as its parent, will benefit.		16 above ☐ Check if None regulations, commercially benefit Novartis Con
Signa	ature DM Koe		Date _ 2/7/0 2

Rurt Rosen - Senior Vice President Filing #e2656c93-8772-4a02-91cc-f04062762ab0 - Page 13 of 22

Printed Name and Title	Date 14050H Delitor Fice 1	l resident	Pag
	·		

Registrant Name: Novartis

Client Name: Novartis Corporation

Item	Description	Data
16	Lobbying Issues	Medicare Prescription Drug & Modernization Act The Bipartisan Medicare Prescription Drug Act of 2001 (Sen. Kennedy-Draf President Bush's "Helping Hand" proposal Prospective Payment System Medicare Reform

Registrant Nam	Novartis Novartis	
Client Name:	Novartis Corporation	
engaged in lobb		y to reflect the general issue areas in which the registrant ng period. Using a separate page for each code, provid l.
15. General is	sue area code <u>TAX</u> (one per page)	•
16. Specific L		
R&D Tax	Credit	
) 	
		t
		•
	, 1 3	_
	of Congress and Federal agencies contacted Representatives	☐ Check if None
Senate		
		*
	•	
10 NT		
is. Name of e	ach individual who acted as a lobbyist in this	issue area
Name	,	Covered Official Position (if applicable)
Duales Da		
Drake, Da		
Elkin, Jan	nes	
Haller, Sa	ırah	:
Rosen, Bu	ort	
,		
) 	49
	¥ 1	<u> </u>
•	5 4	
10 T -		<u>.</u>
	each foreign entity in the specific issues listed AG To the degree that nublic policies, either	l on line 16 above
	tis AG, as its parent, will benefit.	or regulations, commercially benefit 190varus
	$\mathcal{D} + \mathcal{O}$	
a	Land Han	2/7/0
Signature		$^{\circ}$ Date $^{\circ}$ / / $^{\circ}$

Rurt Rosen - Senior Vice President Filing #e2656c93-8772-4a02-91cc-f04062762ab0 - Page 17 of 22

Registra	ant Name: Novartis	
Client N	Name: Novartis Corporation	
engageo informa	d in lobbying on behalf of the client during the reportation as requested. Attach additional page(s) as neede	
	eneral issue area code TRD (one per page	
Ec SR	pecific Lobbying issues conomic Sanctions RM Ban/BSE	
Fa	hina/World Trade Organization ast Track Negotiating Authority apital Market Sanctions	
		,
		_ :
De Fo He	couse(s) of Congress and Federal agencies contacted epartment of Commerce cood & Drug Administration couse of Representatives contacted	☐ Check if None
50.		
18. Na	nme of each individual who acted as a lobbyist in this	s issue area
Na	nme	Covered Official Position (if applicable)
Ha	aller, Sarah	
Ro	osen, Burt	ŕ
		·
		a a a and and a
		ř
	,	
No	erest of each foreign entity in the specific issues listence vartis AG To the degree that public policies, either Novartis AG, as its parent, will benefit.	ed on line 16 above Check if None r laws or regulations, commercially benefit Novartis Con
٠	\mathcal{L}_{α}	
Signatur	ro 1 VIIVI KILA-	Data (#1///)

Rurt Rosen - Senior Vice President Filing #e2656c93-8772-4a02-91cc-f04062762ab0 - Page 19 of 22

Р	rinted Name and Title	Muit Koden	vice a resident	 		Pag
				·		5
				•		
						•

Registrant Na	me: Novartis							
Client Name:	Novartis Cor	Novartis Corporation						
: Informati	on Update Page	e - Complete ONLY who	ere registration information h	as changed.				
20. Client ne	w address	· · · · · · · · · · · · · · · · · · ·						
21. Client ne	w principal place of busin	ness (if different from line 20)						
City		State/Zip (or Country)						
22. New gene	eral description of client's	business or activities	· · · · · · · · · · · · · · · · · · ·	 				
		ported individual who is n	o longer expected to act as a lo	obbyist for the client				
	; 							
	i							
ISSUE UP	nr.		. •					
24. Genera	l loobying issues pre	viously reported that no lo	onger pertain					
	d d							
AFFILIAT	ΓΕĎ ORGANIZA	TIONS	 					
25. Add the	e following affiliated	organization(s)						
	er er			Principal Place of Bu				
	Name		Address	(city and state or cou				
) ;			·				
26. Name o	of each previously re	ported organization that is	no longer affiliated with the re	gistrant or client				
	NENTITIES e following foreign e	ntition						
27. Add the	c ronowing roreign e	Hereico	Principal Place of Busines	ss Amount of contribution				
N: N:	ame	Address	(city and state or country)					
	H							
	of each previously re lated organization	ported foreign entity that I	no longer owns, or controls, or	is affiliated with the registra				
		7	 					
Signature	L //s	12/ Kose-	Γ	Date $\frac{2}{\sqrt{7/0}}$				
			,					
***	: Rart Ro Filing #e2	sen - Senior Vice Preside 656c93-8772-4a02-91cc-f0	ont 4062762ab0 - Page 21 of 22					

	Printed Name and Titl	le		 Pag
•)		1	
	·			
	Į .			
	i l			